^
    Back
    Association details:
    Biomarker:HER-2 positive
    Cancer:Colorectal Cancer
    Drug:trastuzumab botidotin (A166) (HER2-targeted antibody-drug conjugate, Tubulin inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

    Excerpt:
    ...Evaluable or measurable HER2 positive (by ISH or NGS) disease or HER2 expressing disease....
    Trial ID:
    NCT03602079
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    A first in-human study of A166 in patients with locally advanced/metastatic solid tumors which are HER2-positive or HER2-amplified who did not respond or stopped responding to approved therapies.

    Published date:
    05/13/2020
    Excerpt:
    A166 demonstrated clinically meaningful efficacy in heavily pretreated patients with relapsed or refractory advanced solid cancers. The achievement of an ORR of 36% at efficacious dose levels and up to 100% in HER2 positive patients regardless of histology (2 CRC, 1 BC and 1 NSCLC) at the highest studied dose level exceed.
    DOI:
    10.1200/JCO.2020.38.15_suppl.1049
    Trial ID:
    NCT03602079